Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program

DUBLIN Oct. 3 2016 PRNewswire &160;Allergan plc NYSE AGN today announced that it has entered into a licensing agreement with MedImmune AstraZeneca's global biologics research and development arm for the global rights to MEDI2070. MEDI2070 is an antiIL2...